LUCENTIS

Opinions on drugs - Posted on Jan 24 2013

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals.

Clinical Benefit

Comments	In view of the absence of data on the efficacy and tolerability of LUCENTIS in non-subfoveal wet AMD, the committee cannot comment on the actual medical benefit provided by LUCENTIS for this type of condition.
Substantial	The actual medical benefit provided by LUCENTIS is substantial in the case of subfoveal wet AMD.

Clinical Added Value

important

LUCENTIS 10 mg/ml, solution for injection, provides a significant improvement in actual benefit (level II) in the management of patients with AMD and subfoveal CNV.